Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.

Daniela BianconiMerima HeracFlorian PoschMargit SchmeidlMatthias UnseldMarkus KielerRobert BrettnerLeonhard MüllauerJakob RiedlArmin GergerWerner ScheithauerGerald Prager

Published in: Therapeutic advances in medical oncology (2020)

These results can contribute to the development of a personalized strategy for the treatment of mCRC with bevacizumab.

Keyphrases

metastatic colorectal cancer
phase ii study
end stage renal disease
newly diagnosed
chronic kidney disease
locally advanced
ejection fraction
open label
peritoneal dialysis
combination therapy
rectal cancer
replacement therapy
patient reported outcomes